Prostate Cancer

The objective of androgen deprivation therapy (ADT) in men with prostate cancer is to maintain very low levels of testosterone so that the hormone does not promote tumor growth. But a new analysis found that drugs commonly used to achieve this are administered later than the recommended 28-day regimen, and this late dosing was associated with ineffective suppression of testosterone. "Evidence suggests achieving and sustaining T levels <20 mg/dL with ADT is desirable and correlates with improved disease-specific survival in patients with advanced prostate cancer," lead author David Crawford, MD, professor of urology, University of California, San Diego, and colleagues point out. They looked at administration schedules for luteinizing hormone-releasing hormone (LHRH) agonists and found that they were frequently (84%) administered later than the recommended schedule of every 28 days. Nearly half of the late testosterone values for the extended month were greater than 20 ng

Robotic assistance significantly improves continence rates in radical prostatectomy: Study Top We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings. Ok

Patient visits for cancer care have decreased significantly since the onset of the COVID-19 pandemic, according to one of the first systematic studies supporting anecdotal reports. ( Jefferson Health , JCO Clinical Cancer Informatics ) One-fourth of patients with previously treated high-risk myelodysplastic syndromes responded to selinexor (Xpovio), and another 52% had stable disease. ( The Lancet Haematology ) AstraZeneca and Daiichi Sankyo entered into a second multibillion dollar oncology agreement in as many years, this time to develop an antibody-drug conjugate cancer therapy targeting TROP-2. ( Reuters ) A television news reporter learned she had thyroid cancer after a viewer wrote her about a suspicious lump on the reporter's neck. ( CNN ) GlaxoSmithKline and genetic-testing company 23andMe launched a cancer clinical study, the first of multiple planned early-stage trials to use genetic information to develop new drugs. ( Bloomberg ) Two lung cancer organizations announ

There was no difference in the occurrence of late toxicities, which was low, between 2 arms of patients treated with radiotherapy alone or radiotherapy with short-term androgen deprivation therapy (STADT) with degarelix as treatment of patients prostate cancer with detectable prostate-specific antigen (PSA) after a radical prostatectomy, according to the phase 2 GETUG-AFU 22 study. Results were presented in a poster during the 35th Annual European Association of Urology Virtual Congress by Paul Sargos, MD, of Insitut Bergonié, in Bordeaux, France. The GETUG-AFU 22 study is a multicenter, randomized study. A total of 125 patients were enrolled between December 2012 and September 2015, which led to 64 patients included in the radiotherapy arm (arm A) and 61 patients in the radiotherapy plus STADT arm (arm B). The primary end point of the study was event-free survival, and the secondary end points included 5-year EFS and metastases-free survival, 5- and 10-year overall survival, acute

An Israeli startup developing a digital pathology system based around artificial intelligence has published what it calls “outstanding outcomes” in a clinical validation study. Tel Aviv-based Ibex Medical Analysis said Tuesday that it had published data on Galen Prostate, its AI-based system for use by pathologists to detect and measure prostate cancer, in The Lancet Digital Health. The company called it the first and only AI-based system used by pathologists in routine clinical practice. The study took place at the University of Pittsburgh Medical Center, led by Drs. Liron Pantanowitz and Rajiv Dhir, both pathologists at UPMC’s Shadyside Hospital. According to the data, sensitivity measured for prostate cancer was 98.46%, and specificity was 97.33%, while the operating characteristic curve was 0.991. The company said all of these were higher than previously reported metrics for AI algorithms in pathology, and that this was the first such algorithm to go beyond detection and extend

PITTSBURGH (Newsradio 1020 KDKA) In a study published today in the Lancet Digital Health, UPMC and the University of Pittsburgh School of Medicine has demonstrated the highest accuracy in recognizing and characterizing prostate cancer by using artificial intelligence (AI).   “Humans are good at recognizing anomalies, but they have their own biases or past experience,” senior author  Rajiv Dhir, M.D., M.B.A. , chief pathologist and vice chair of pathology at UPMC Shadyside and professor of biomedical informatics at Pitt said. Dhir said that using AI adds an element of standardizing care. In training the AI to recognize prostate cancer, Dhir and his colleagues provided more than a million images of stained tissue slides from patient biopsies. Each image was labeled by an expert to teach the AI how to identify healthy or abnormal tissue. The algorithm was tested on 1,600 different slides taken from 100 consecutive patients seen at UPMC suspected prostate cancer. The AI demonstrated

Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Credit: Ibex Medical Analytics A study published today (July 27, 2020) in The Lancet Digital Health  by UPMC and University of Pittsburgh researchers demonstrates the highest accuracy to date in recognizing and characterizing prostate cancer using an artificial intelligence (AI) program. “Humans are good at recognizing anomalies, but they have their own biases or past experience,” said senior author Rajiv Dhir, M.D., M.B.A., chief pathologist and vice chair of pathology at UPMC Shadyside and professor of biomedical informatics at Pitt. “Machines are detached from the whole story. There’s definitely an element of standardizing care.” To train the AI to recognize prostate cancer, Dhir and his colleagues provided images from more than a million parts of stained tissue slides

There exists a correlation between diet and prostate cancer, according to the findings a recent Canada-based study published in the journal Nutrients. This study was based on the analysis of three dietary profiles: a healthy diet; a salty Western diet (including alcohol); and a sugar-rich Western diet with beverages. The healthy diet is rich in fruits, vegetables, and plant proteins such as tofu and nuts.  The salty Western diet with alcohol consists of more meat and alcoholic beverages such as beer and wine, while third profile comprises pasta, pizza, desserts, and sugary carbonated drinks. The researchers accounted for age, ethnicity, education, family history, and date of last prostate cancer screening into account. “It’s not easy to isolate the effect of a single nutrient,” said Institut national de la recherche scientifique (INRS) PhD student Karine Trudeau, the lead author of the study in a press release. “For example, foods rich in vitamin C, such as citrus fruits, promote

There are genetic differences when comparing prostate tumors from African American men and European-American men, but none of these differences are of clinical significance for the genetically targeted treatments available to date, according to an analysis published in Clinical Cancer Research. "[N]o significant differences were seen in clinically actionable DNA repair genes, MSI-high [microsatellite instability–high] status, and tumor mutation burden, suggesting that current therapeutic strategies may be equally beneficial in both populations," wrote study author Yusuke Koga, of the Boston University, and colleagues. "Since these findings suggest that the frequency of targetable genetic alterations is similar in patients of predominantly African versus European ancestry, offering comprehensive genomic profiling and biomarker-based therapies to all patients, including African American patients, is a critical component of promoting equity in the management of metastati

There are genetic differences when comparing prostate tumors from African American men and European-American men, but none of these differences are of clinical significance for the genetically targeted treatments available to date, according to an analysis published in Clinical Cancer Research. "[N]o significant differences were seen in clinically actionable DNA repair genes, MSI-high [microsatellite instability–high] status, and tumor mutation burden, suggesting that current therapeutic strategies may be equally beneficial in both populations," wrote study author Yusuke Koga, of the Boston University, and colleagues. "Since these findings suggest that the frequency of targetable genetic alterations is similar in patients of predominantly African versus European ancestry, offering comprehensive genomic profiling and biomarker-based therapies to all patients, including African American patients, is a critical component of promoting equity in the management of metastati

This article was originally published here Urology. 2020 Jul 22:S0090-4295(20)30857-8. doi: 10.1016/j.urology.2020.05.096. Online ahead of print. ABSTRACT OBJECTIVE: To evaluate existing practice patterns and potential barriers to implementing opioid stewardship protocols after robot-assisted prostatectomies among providers in the Pennsylvania Urology Regional Collaborative. METHODS: The Pennsylvania Urology Regional Collaborative (PURC) is a voluntary quality improvement initiative of 11 academic and community urology practices in Pennsylvania and New Jersey representing 97 urologists. PURC distributed a web-based survey of 24 questions, with 74 respondents, including 56 attendings, 11 residents, and 7 advanced practice providers. RESULTS: More pills were prescribed if there was a default number of pills from the electronic health record (median 30) then if the number of pills was manually placed (p=0.01). Only 8% discussed how to dispose of opioids with their patients, and les

publication date: Jul. 24, 2020 Real-World Evidence Payment policies blamed for non-compliance with treatment guidelines By Matthew Bin Han Ong The vast majority of patients with prostate cancer in the United States don’t receive androgen deprivation therapy injections on time. Up to 84% of injections are delayed for patients on a 28-day schedule, according to an authoritative study published in the The Journal of Urology . T he study, conducted by researchers from more than a dozen institutions, used real-world claims data from 22,860 patients with prostate cancer who were treated with luteinizing hormone-releasing agonists and who had one measurement of PSA or testosterone. The retrospective analysis included data from January 2007 through June 2016. Delays in hormone therapy should be avoided to prevent adverse outcomes, prostate cancer experts say. Multiple studies have established a relationship between maintaining testosterone at castration levels and lowered risk of prog

DUBLIN , July 24, 2020 /PRNewswire/ -- The "Prostate Cancer - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth understanding of the Prostate Cancer, historical and forecasted epidemiology as well as the Prostate Cancer market trends in the United States , EU5 ( Germany , France , Italy , Spain , and United Kingdom ), and Japan . The report provides current treatment practices, emerging drugs, Prostate Cancer market share of the individual therapies, current and forecasted Prostate Cancer market size from 2017 to 2030 segmented by seven major markets. The report also covers current Prostate Cancer treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market. Epidemiology The Prostate Cancer epidemiology division provide the insights about historical an

(UroToday.com) The focal therapy for prostate cancer thematic session at the European Association of Urology (EAU) Virtual 2020 meeting annual meeting featured two talks on outcomes of salvage radical prostatectomy after focal therapy, with Sebastien Crouzet, MD, PhD, discussing the ability to achieve good function and pathological results after this procedure. Dr. Crouzet notes that strict patient selection for focal therapy is essential and must include (i) a multi-parametric magnetic resonance imaging (mpMRI) scan plus randomized and targeted biopsies, (ii) careful guidance and a safety margin during treatment, and (iii) a follow-up mpMRI and biopsy at one-year post-treatment. Furthermore, focal therapy should be performed on trials, it may be repeated if needed, and it still allows for salvage treatment options. Regarding a salvage prostatectomy after focal therapy, there are several requirements for performing an adequate operation, including (i) an experienced surgeon, (ii) pr

More men than expected experience significant urinary incontinence and erectile dysfunction following prostate cancer (PCa) treatment, according to results of a new international survey presented at the European Association of Urology 2020 virtual congress. The Europa Uomo Patient Reported Outcomes Study (EUPROMS) included 2943 European men (mean age 70 years and mean age at diagnosis 64 years) from 25 countries treated for PCa. Patients responded online to the Expanded Prostate Cancer Index Composite (EPIC-26), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire version 3.0 (EORTC-QLQ-C30), and EQ-5D-5L. Two-thirds of patients underwent 1 PCa treatment and 22%, 10%, and 2% had 2, 3, or 4 or more treatments, respectively. Half of patients reported that loss of sexual function (including the ability to have an erection or reach orgasm) was a “big” (28%) or “moderate” (22%) problem for them; 82% were currently living with a partner. Chemotherapy,

More men than expected experience significant urinary incontinence and erectile dysfunction following prostate cancer (PCa) treatment, according to results of a new international survey presented at the European Association of Urology 2020 virtual congress. The Europa Uomo Patient Reported Outcomes Study (EUPROMS) included 2943 European men (mean age 70 years and mean age at diagnosis 64 years) from 25 countries treated for PCa. Patients responded online to the Expanded Prostate Cancer Index Composite (EPIC-26), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire version 3.0 (EORTC-QLQ-C30), and EQ-5D-5L. Two-thirds of patients underwent 1 PCa treatment and 22%, 10%, and 2% had 2, 3, or 4 or more treatments, respectively. Half of patients reported that loss of sexual function (including the ability to have an erection or reach orgasm) was a “big” (28%) or “moderate” (22%) problem for them; 82% were currently living with a partner. Chemotherapy,

Germline testing is an increasingly crucial component of the assessment, management, and treatment of prostate cancer. Once identified, relevant gene mutations can alert physicians when patients are at an elevated risk of disease or, when metastatic disease is already present, steer patients toward the precision therapies most likely to benefit them. But taking full advantage of germline testing requires staying up to date on the latest data, which is no small challenge for clinicians given how quickly the field is developing. Veda Giri, MD It was therefore welcome news when the Philadelphia Prostate Cancer Consensus Conference was convened in 2019 to take stock of these developments in germline testing and provide clinicians with guidelines on its use. With those guidelines now made available in the Journal of Clinical Oncology , Medscape reached out to lead author Veda Giri, MD, associate professor of medical oncology, cancer biology and urology, and director of cancer risk asses

Germline testing is an increasingly crucial component of the assessment, management, and treatment of prostate cancer. Once identified, relevant gene mutations can alert physicians when patients are at an elevated risk of disease or, when metastatic disease is already present, steer patients toward the precision therapies most likely to benefit them. But taking full advantage of germline testing requires staying up to date on the latest data, which is no small challenge for clinicians given how quickly the field is developing. Veda Giri, MD It was therefore welcome news when the Philadelphia Prostate Cancer Consensus Conference was convened in 2019 to take stock of these developments in germline testing and provide clinicians with guidelines on its use. With those guidelines now made available in the Journal of Clinical Oncology , Medscape reached out to lead author Veda Giri, MD, associate professor of medical oncology, cancer biology and urology, and director of cancer risk asses